Trial Profile
A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200 mg BID) for 10 days Compared with Fidaxomicin (200 mg BID) for 10 days for the Treatment of Clostridium difficile Infection (CDI)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2018
Price :
$35
*
At a glance
- Drugs Ridinilazole (Primary) ; Fidaxomicin
- Indications Clostridium difficile infections
- Focus Adverse reactions
- Acronyms CoDIFy 2
- Sponsors Summit Therapeutics
- 07 Oct 2018 Results presented at the IDWeek 2018
- 09 Oct 2017 Results from this trial were presented at IDWeek 2017, according to a Summit Therapeutics media release.
- 08 Oct 2017 Results presented at the IDWeek 2017